Division of Nephrology and Kidney Center, Kobe University Graduate School of Medicine, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
Clin Exp Nephrol. 2013 Jun;17(3):365-71. doi: 10.1007/s10157-012-0717-0. Epub 2012 Oct 26.
Vascular calcification is associated with mortality and cardiovascular events in patients with chronic kidney disease. AST-120, which adsorbs uremic toxins, is reported to reduce the risk of cardiovascular disease and death in chronic kidney disease patients. The aim of the current study was to investigate the association between abdominal aortic calcification and the use of AST-120 in predialysis chronic kidney disease patients.
A retrospective analysis was conducted including 199 predialysis chronic kidney disease patients (stages 4 and 5) who underwent abdominal plain computed tomography in our institution between 2005 and 2010. Abdominal aortic calcification was assessed by aortic calcification index (ACI). Patients were divided into two groups based on whether or not AST-120 was administered for at least six months, and ACI was compared between the two groups.
The aortic calcification index was significantly lower in patients taking AST-120 [12.2 (2.5-30.3) vs. 25.7 (13.4-45.3) %, P < 0.001]. According to multivariate linear regression analysis, the use of AST-120 was independently and significantly correlated with ACI after adjusting for confounding factors.
The use of AST-120 was independently associated with less aortic calcification in predialysis chronic kidney disease patients.
血管钙化与慢性肾脏病患者的死亡率和心血管事件相关。AST-120 可吸附尿毒症毒素，据报道可降低慢性肾脏病患者发生心血管疾病和死亡的风险。本研究旨在探讨腹主动脉钙化与透析前慢性肾脏病患者使用 AST-120 之间的关系。
回顾性分析了 2005 年至 2010 年间在我院接受腹部平扫 CT 的 199 例透析前慢性肾脏病患者（4 期和 5 期）。采用主动脉钙化指数（ACI）评估腹主动脉钙化。根据是否至少使用 AST-120 治疗 6 个月将患者分为两组，并比较两组之间的 ACI。
使用 AST-120 的患者的主动脉钙化指数明显较低[12.2（2.5-30.3）%比 25.7（13.4-45.3）%，P<0.001]。根据多变量线性回归分析，在校正混杂因素后，AST-120 的使用与 ACI 独立且显著相关。
在透析前慢性肾脏病患者中，AST-120 的使用与主动脉钙化程度较轻独立相关。
